Last reviewed · How we verify

NCT04962815

Ceribell Delirium Data Collection Study

Recruiting now Last updated 25 July 2025
What this trial tests

trial testing Electroencephalogram (EEG) Test in Delirium in 200 participants. Currently enrolling.

Timeline
10 November 2021
Primary endpoint
31 December 2025
1 April 2026

Quick facts

Lead sponsorCeribell Inc.
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment200
Start date10 November 2021
Primary completion31 December 2025
Estimated completion1 April 2026
Sites7 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Ceribell Inc. — full company profile →

Who can join

18 and older, any sex, with Delirium. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed as a prospective, non-randomized, observational clinical study. The study will collect clinical and rrEEG (Ceribell EEG) data when monitoring subjects for delirium subtypes. EEG and clinical data will be collected for the development of future software algorithms to assess the presence and severity of delirium.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Delirium

Currently open trials in the same condition.

Other Ceribell Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04962815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing